Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

ACTIVE NOT RECRUITING

NCT04423731

Sponsor: Oslo University Hospital

Summary

This is a Norwegian prospective observational study that evaluates the resectability rate in patients with borderline resectable and locally advanced pancreatic cancer who received neoadjuvant chemotherapy in a population based cohort. Eligible patients are treated with neoadjuvant chemotherapy possibly followed by surgical exploration and resection. All Norwegian centres performing pancreatic surgery have agreed to collaborate in this trial. The assignment of the medical intervention is not at the discretion of the investigator, but follow the national Norwegian guidelines regarding diagnostic work up, oncological and surgical treatment and follow up.

Official title: Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer - A Norwegian Population Based Observational Study (NORPACT-2)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

OBSERVATIONAL

Enrollment

251

Start Date

2018-01-01

Completion Date

2025-12-31

Last Updated

2024-11-20

Healthy Volunteers

Not specified

Conditions

Locally Advanced Pancreatic Adenocarcinoma Chemotherapy Effect Borderline Resectable Pancreatic Adenocarcinoma Pancreatectomy

Interventions

DRUG

Folfirinox

Neoadjuvant chemotherapy is given according to different regimens, preferably FOLFIRINOX according to the recommendations in the national Norwegian guidelines. The choice of chemotherapy regimen is decided by the treating oncologist.

Locations (1)

Oslo University Hospital

Oslo, Norway

Clinical Research Directory